|Outcome||Relative effect 95%CI||LoD||Trt. better when||I2||k (RCT/OBS)||Bayesian probability||Overall ROB||Publication bias||Degree of certainty||Endpoint importance||Published MA|
|clinical improvement||1.36 [0.87, 2.11]||> 1||0%||1 study (1 / -)||91.0 %||some concern||not evaluable||moderate||crucial||-|
|clinical improvement (14-day)||1.36 [0.87, 2.11]||> 1||0%||1 study (1 / -)||91.0 %||some concern||not evaluable||moderate||crucial||-|
|deaths||1.01 [0.06, 16.28]||< 1||0%||1 study (1 / -)||49.7 %||some concern||not evaluable||moderate||crucial||-|
LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.